Category Archives: Cardiovascular Pharmacology

Laith Alexander, University of Cambridge; Angela Charlotte Roberts, University of Cambridge, and Christian Wood, University of Cambridge Although depression and anxiety affect millions of people worldwide, theres still much we dont know about them. In fact, we still dont fully understand which brain regions are involved in depression and anxiety, and how they differ between people with varying symptoms Continue reading →

472 0 Posted on Nov 03, 2020, 4 p.m. According to a report published in the Journal of the American College of Cardiology the regular consumption of hot chilli peppers is associated with a lower risk of dying from cardiovascular disease or any cause, independent of CVD risk factors or adherence to a Mediterranean style diet Continue reading →

SMT Completes Enrolment of Cruz HBR Registry to Further Evaluate the Safety and Efficacy of Supraflex Cruz in High Bleeding Risk Patients Sahajanand Medical Technologies Pvt. Ltd. Continue reading →

November 02, 2020 16:00 ET | Source: INVENTIVA multilang-release Daix (France), November 2, 2020 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the role of peroxisome proliferator-activated receptors (PPARs) in the treatment of NASH by the peer-reviewed medical journal Nature Review Gastroenterology & Hepatology. Published in coordination with the panNASH initiative, the article, entitled Non-alcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors, discusses the current literature on Non-Alcoholic Fatty Liver Disease (NAFLD), describes the role of PPARs in NASH and related metabolic diseases, and summarizes the preclinical and clinical data on the use of PPAR agonists. NAFLD is a multisystem disease with extra-hepatic disease implications, including the development of type two diabetes (T2DM) and cardiovascular diseases (CVDs) Continue reading →

Cortisone Market: Overview Cortisone markets evolution stems from the therapeutic effect of corticosteroid with glucocorticoid activity. The popularity in therapeutic application is triggered by wide spectrum of applications of systemic corticosteroid therapy. It has been popularly used in patients with adrenal insufficiency Continue reading →

COVID-19 impact will also be included and considered for forecast. Continue reading →

Oct. 13, 2020 12:00 UTC -- Company to present Phase 1 safety, tolerability and TRPC5-Rac1 pathway target engagement data at American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting -- -- Additional poster presentations to showcase GFB-887s novel urinary Rac1 predictive biomarker strategy and companys proprietary precision medicine platform -- -- Kidney and Cardio-Metabolic R&D expert, Gus Gustafson, Ph.D., joins Goldfinch Bio as Senior Vice President, Discovery and Translational Biology -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present clinical data from a Phase 1 study of its lead precision kidney therapeutic candidate, GFB-887, at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting, taking place virtually October 22-25, 2020. Goldfinch is developing GFB-887, a first-in-class, highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-Rac1 pathway Continue reading →

As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, its now more important than ever to have a thorough assessment of the safety of these medications. Continue reading →

Anti-malaria drugs taken by Donald Trump to prevent contracting Covid-19 could increase the risk of cardiovascular disease by 30 times, new research warns. Side effects include irregular heart beats, heart failure and damage to the organ's muscle, all of which are life threatening, say scientists. Senior author Professor Elad Maor, of Tel-Aviv University, Israel, said: "Moreover, we show how these adverse events carry high risks for severe outcomes including death, even with standard doses of the drugs." It was confirmed by the White House in May Donald Trump had been taking hydroxychloroquine every day for two weeks. Continue reading →

Anti-malaria drugs touted by Donald Trump to protect against Covid-19 could increase the risk of cardiovascular disease almost thirty-fold, warns new research. Continue reading →